Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACELYRIN, Inc.SLRN · Entity 79310 | CFO and CBO | August 31, 2024 | September 04, 2024 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | SVP, COO & CFO | May 15, 2022 | May 18, 2022 |
| Rezolute, Inc.RZLT · Entity 1990 | Director | November 19, 2025 | November 21, 2025 |
| Septerna, Inc.SEPN · Entity 2452 | Chief Financial Officer | February 06, 2026 | February 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACELYRIN, Inc.
Report date August 31, 2024 · Filed September 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.78 · Expires 2034-08-30 | Direct | 150,000 |
Reported balance
After 2024-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-31 · Grant · Acquired 150,000 · Balance 150,000 F1: 1/4 of the shares subject to the option vest on August 31, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4 of the shares subject to the option vest on August 31, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
NEKTAR THERAPEUTICS
Report date May 15, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 330,353 |
Reported balance
After 2022-05-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-15 · Grant · Acquired 28,750 · Balance 330,353 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied. F3: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 312,905 |
Reported balance
After 2022-05-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-05-16 · Sale · Disposed 17,448 · Balance 312,905 F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
F2: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied.
F3: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F5: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Rezolute, Inc.
Report date November 19, 2025 · Filed November 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 55,500 |
Reported balance
After 2025-11-19 transaction · row 1
1 source rowRow 1 · 2025-11-19 · Grant · Acquired 21,000 · Balance 55,500 F1: Represents grant of restricted stock units which fully vest on December 1, 2026. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2035-11-19 | Direct | 12,000 |
Reported balance
After 2025-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-19 · Grant · Acquired 12,000 · Balance 12,000 F2: The options fully vest on December 1, 2026. |
| Common SharesSEC Table I · non-derivative | IndirectThe Labrucherie Trust dated 9/1/2009 | 53,572 |
Reported balance
Holding disclosure · report date 2025-11-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 53,572 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units which fully vest on December 1, 2026.
F2: The options fully vest on December 1, 2026.
Septerna, Inc.
Report date February 06, 2026 · Filed February 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.41 · Expires 2036-02-05 | Direct | 125,000 |
Reported balance
After 2026-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-06 · Grant · Acquired 125,000 · Balance 125,000 F1: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2018 Filed May 4, 2018 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 30,000 | $10.69 | $320,700.00 |
DisclosureSEC source: 0001209191-18-027942 · doc4.xml · nonDerivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring in the next 12 months. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 01, 2018 Filed May 4, 2018 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-027942 · doc4.xml · derivative · entry 7 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 30,000 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring in the next 12 months. Read SEC document |
| May 01, 2018 Filed May 4, 2018 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 30,000 | $83.65 | $2,509,500.00 |
DisclosureSEC source: 0001209191-18-027942 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,739 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring in the next 12 months. F3 · price: This transaction was executed in multiple trades at prices ranging from $82.60 to $84.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 01, 2018 Filed May 4, 2018 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 30,000 | $10.69 | $320,700.00 |
DisclosureSEC source: 0001209191-18-027942 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring in the next 12 months. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 00:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,477 | $82.94 | $288,382.38 |
DisclosureSEC source: 0001209191-18-011592 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,739 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.57 to $84.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 23:27 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 65,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-17-066479 · doc4.xml · derivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2025-12-14 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 23:27 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066479 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,216 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Disposition to issuerCommon Stock | 6,698 | $44.23 | $296,252.54 |
DisclosureSEC source: 0001209191-17-061592 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,716 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $41.98 to $45.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $14.41 | $0.00 |
DisclosureSEC source: 0001209191-17-061592 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-12-12 F6 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 13, 2016). F7 · date: These stock options were granted on December 13, 2016 and the performance-based vesting requirement for these stock options was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro CPI). F8 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061592 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,414 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 13, 2016, were subject to both performance-based and time-based vesting requirements. On November 15, 2017, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: These restricted stock units ("RSUs") were granted on December 13, 2016 and the performance-based vesting requirement for these RSUs was satisfied on November 15, 2017 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for Ciprofloxacin Dry Powder Inhalation (Cipro DPI). F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 22:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 120,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-17-055360 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on May 22, 2017 related to 120,000 stock options scheduled to expire on January 31, 2018. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 22:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 120,000 | $24.45 | $2,934,000.00 |
DisclosureSEC source: 0001209191-17-055360 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,414 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on May 22, 2017 related to 120,000 stock options scheduled to expire on January 31, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.99 to $24.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 22:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 120,000 | $11.34 | $1,360,800.00 |
DisclosureSEC source: 0001209191-17-055360 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on May 22, 2017 related to 120,000 stock options scheduled to expire on January 31, 2018. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 23:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,177 | $19.32 | $61,379.64 |
DisclosureSEC source: 0001209191-17-049666 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,414 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.02 to $19.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 16, 2017 Filed May 19, 2017 00:48 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,179 | $19.55 | $62,149.45 |
DisclosureSEC source: 0001209191-17-033769 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,091 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.31 to $19.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| March 03, 2017 Filed Mar 4, 2017 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-17-018033 · doc4.xml · derivative · entry 9 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2017-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 25,000 stock options scheduled to expire on November 17, 2017. Read SEC document |
| March 03, 2017 Filed Mar 4, 2017 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 7,494 | $0.00 Strike: $6.34 | $0.00 |
DisclosureSEC source: 0001209191-17-018033 · doc4.xml · derivative · entry 8 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,494 shares Expires 2017-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 175,000 stock options scheduled to expire on June 9, 2017. Read SEC document |
| March 03, 2017 Filed Mar 4, 2017 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 25,000 | $15.21 | $380,250.00 |
DisclosureSEC source: 0001209191-17-018033 · doc4.xml · nonDerivative · entry 6 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,270 F5 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 25,000 stock options scheduled to expire on November 17, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| March 03, 2017 Filed Mar 4, 2017 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $9.24 | $231,000.00 |
DisclosureSEC source: 0001209191-17-018033 · doc4.xml · nonDerivative · entry 5 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 25,000 stock options scheduled to expire on November 17, 2017. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| March 03, 2017 Filed Mar 4, 2017 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,494 | $15.21 | $113,983.74 |
DisclosureSEC source: 0001209191-17-018033 · doc4.xml · nonDerivative · entry 4 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,270 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 175,000 stock options scheduled to expire on June 9, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| March 03, 2017 Filed Mar 4, 2017 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 7,494 | $6.34 | $47,511.96 |
DisclosureSEC source: 0001209191-17-018033 · doc4.xml · nonDerivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 175,000 stock options scheduled to expire on June 9, 2017. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 167,506 | $0.00 Strike: $6.34 | $0.00 |
DisclosureSEC source: 0001209191-17-018033 · doc4.xml · derivative · entry 7 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,494 Underlying: Common Stock · 167,506 shares Expires 2017-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 175,000 stock options scheduled to expire on June 9, 2017. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 167,506 | $15.15 | $2,537,715.90 |
DisclosureSEC source: 0001209191-17-018033 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,270 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 175,000 stock options scheduled to expire on June 9, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 167,506 | $6.34 | $1,061,988.04 |
DisclosureSEC source: 0001209191-17-018033 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 175,000 stock options scheduled to expire on June 9, 2017. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2017 Filed Feb 18, 2017 01:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,359 | $13.14 | $30,997.26 |
DisclosureSEC source: 0001209191-17-012405 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,270 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.94 to $13.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 01:45 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001209191-16-155519 · doc4.xml · derivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-12-12 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 01:45 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-155519 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,629 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in equal quarterly installments based on continued service. F2 · balance_after: This number includes 997 shares held by the reporting person from the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 23:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,654 | $13.96 | $23,089.84 |
DisclosureSEC source: 0001209191-16-151303 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,129 F1 · price: This transaction was executed in multiple trades at prices ranging from $13.71 to $14.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(k) plan and 2,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.